Targeting transcription factors in cancer — from undruggable to reality
| Autor: | John H. Bushweller |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Proteasome Endopeptidase Complex
General Mathematics Antineoplastic Agents Ligands Article 03 medical and health sciences 0302 clinical medicine Ubiquitin Transcription (biology) Catalytic Domain Cell Line Tumor Neoplasms Protein Interaction Mapping Gene expression Gene duplication Animals Humans Phosphorylation Transcription factor Cell Proliferation Regulation of gene expression biology Kinase Applied Mathematics Point mutation Ubiquitination DNA Cell biology Gene Expression Regulation Neoplastic Drug Design 030220 oncology & carcinogenesis Mutation Proteolysis biology.protein Protein Processing Post-Translational Protein Binding Transcription Factors |
| Zdroj: | Nat Rev Cancer |
| ISSN: | 1474-1768 1474-175X |
| DOI: | 10.1038/s41568-019-0196-7 |
| Popis: | Mutated or dysregulated transcription factors represent a unique class of drug targets that mediate aberrant gene expression, including blockade of differentiation and cell death gene expression programmes, hallmark properties of cancers. Transcription factor activity is altered in numerous cancer types via various direct mechanisms including chromosomal translocations, gene amplification or deletion, point mutations and alteration of expression, as well as indirectly through non-coding DNA mutations that affect transcription factor binding. Multiple approaches to target transcription factor activity have been demonstrated, preclinically and, in some cases, clinically, including inhibition of transcription factor–cofactor protein–protein interactions, inhibition of transcription factor–DNA binding and modulation of levels of transcription factor activity by altering levels of ubiquitylation and subsequent proteasome degradation or by inhibition of regulators of transcription factor expression. In addition, several new approaches to targeting transcription factors have recently emerged including modulation of auto-inhibition, proteolysis targeting chimaeras (PROTACs), use of cysteine reactive inhibitors, targeting intrinsically disordered regions of transcription factors and combinations of transcription factor inhibitors with kinase inhibitors to block the development of resistance. These innovations in drug development hold great promise to yield agents with unique properties that are likely to impact future cancer treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink